International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

Quality of Life Research

Volumn 27, Issue 2, 2018, Pages 333-345

  van de Poll Franse, Lonneke ^a,b,c   Oerlemans, Simone ^a   Bredart, Anne ^d,e   Kyriakou, Charalampia ^f   Sztankay, Monika ^g   Pallua, Stephan ^g   Daniëls, Laurien ^h   Creutzberg, Carien L ^h   Cocks, Kim ^i,j   Malak, Sandra ^d   Caocci, Giovanni ^k   Molica, Stefano ^l   Chie, Weichu ^m   Efficace, Fabio ⁿ  

^a Netherlands Comprehensive Cancer Organisation ^*  (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d INSTITUT CURIE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f EALING HOSPITAL NHS TRUST   (United Kingdom)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ KCStats Consultancy   (United Kingdom)

^j UNIVERSITY OF YORK   (United Kingdom)

^k UNIVERSITY OF CAGLIARI   (Italy)

^l Azienda Ospedalier Ciaccio   (Italy)

^m NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁿ Italian Group for Adult Hematologic Diseases GIMEMA Data Center   (Italy)

more..

Author keywords

Chronic lymphocytic leukaemia; Hodgkin lymphoma; Non Hodgkin lymphoma; Quality of life; Symptoms

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; EORTC DISEASE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; FEMALE; HEALTH CARE PERSONNEL; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; STEM CELL TRANSPLANTATION; ADOLESCENT; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PSYCHOLOGY; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HODGKIN DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; QUALITY OF LIFE; RESEARCH DESIGN; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85033492986     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-017-1718-y     Document Type: Article

References (47)

1. van de Schans, S. A., Issa, D. E., Visser, O., Nooijen, P., Huijgens, P. C., Karim-Kos, H. E., et al. (2012). Diverging trends in incidence and mortality, and improved survival of non-Hodgkin’s lymphoma, in the Netherlands, 1989–2007. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 23(1), 171–182. doi:10.1093/annonc/mdr055
2. Junlen, H. R., Peterson, S., Kimby, E., Lockmer, S., Linden, O., Nilsson-Ehle, H., et al. (2015). Follicular lymphoma in Sweden: Nationwide improved survival in the rituximab era, particularly in elderly women: A Swedish Lymphoma Registry study. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K, 29(3), 668–676. doi:10.1038/leu.2014.251
3. Mounier, M., Bossard, N., Remontet, L., Belot, A., Minicozzi, P., De Angelis, R., et al. (2015). Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematology, 2(11), e481–e491. doi:10.1016/S2352-3026(15)00155-6
4. Pulte, D., Jansen, L., Castro, F. A., & Brenner, H. (2016). Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer, 122(13), 2031–2040. doi:10.1002/cncr.30003
5. Dutch Cancer Society (2011). Cancer in the Netherlands until 2020, Trends and Prognoses [Kanker in Nederland tot 2020, Trends en prognoses]. KWF Kankerbestrijding, Amsterdam (ISBN 9789071229008)
6. Howlader, N., Noone, A. M., Krapcho, M., Miller, D., Bishop, K., Altekruse, S. F., et al. (2006). SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web site Retrieved from April 2016 http://seer.cancer.gov/csr/1975_2013/.
7. Efficace, F., Kemmler, G., Vignetti, M., Mandelli, F., Molica, S., & Holzner, B. (2008). Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials—a systematic review to evaluate the added value in supporting clinical decision making. European Journal of Cancer, 44(11), 1497–1506.
8. Appelbaum, F. R., Rosenblum, D., Arceci, R. J., Carroll, W. L., Breitfeld, P. P., Forman, S. J., et al. (2007). End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood, 109(5), 1810–1816.
9. Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., et al. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108(2), 419–425.
10. Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., et al. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111(12), 5446–5456.
11. Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., et al. (2009). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood, 113(11), 2386–2393.
12. Tefferi, A., Barosi, G., Mesa, R. A., Cervantes, F., Deeg, H. J., Reilly, J. T., et al. (2006). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 108(5), 1497–1503.
13. Aleman, B. M., & van Leeuwen, F. E. (2007). Are we improving the long-term burden of Hodgkin’s lymphoma patients with modern treatment? Hematology/Oncology Clinics of North America, 21(5), 961–975.
14. Friedman, D. L., & Constine, L. S. (2006). Late effects of treatment for Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network, 4(3), 249–257.
15. Hess, S. L., Johannsdottir, I. M., Hamre, H., Kiserud, C. E., Loge, J. H., & Fossa, S. D. (2011). Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects. Acta Oncologica, 50(5), 653–659. doi:10.3109/0284186X.2010.550934
16. Hodgson, D. C., Grunfeld, E., Gunraj, N., & Del Giudice, L. (2010). A population-based study of follow-up care for Hodgkin lymphoma survivors: Opportunities to improve surveillance for relapse and late effects. Cancer, 116(14), 3417–3425.
17. Ng, A. K., & Mauch, P. M. (2009). Late effects of Hodgkin’s disease and its treatment. Cancer Journal, 15(2), 164–168.
18. Punnett, A., Tsang, R. W., & Hodgson, D. C. (2010). Hodgkin lymphoma across the age spectrum: Epidemiology, therapy, and late effects. Seminars in Radiation Oncology, 20(1), 30–44.
19. Ruiz-Soto, R., Sergent, G., Gisselbrecht, C., Larghero, J., Ertault, M., Hennequin, C., et al. (2005). Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer, 104(12), 2735–2742.
20. Walsh, M. C. (2010). Impact of treatment-related cardiac toxicity on lymphoma survivors: An institutional approach for risk reduction and management. Clinical Journal of Oncology Nursing, 14(4), 505–507.
21. Cella, D., Webster, K., Cashy, J., Kutikova, L., Burgess, M. F., Lin, B. K., et al. (2005). Development of a measure of health-related quality of life for non-Hodgkin’s lymphoma clinical research: The functional assessment of cancer therapy-lymphoma (FACT-Lym). Blood, 106(11), 750.
22. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.
23. Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.
24. Mols, F., Aaronson, N. K., Vingerhoets, A. J., Coebergh, J. W., Vreugdenhil, G., Lybeert, M. L., et al. (2007). Quality of life among long-term non-Hodgkin lymphoma survivors: A population-based study. Cancer, 109(8), 1659–1667.
25. Mols, F., Vingerhoets, A. J., Coebergh, J. W., Vreugdenhil, G., Aaronson, N. K., Lybeert, M. L., et al. (2006). Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: A population-based study. European Journal of Cancer, 42(16), 2794–2801.
26. European Organization for Research and Treatment of Cancer (2011). Retrieved from May 5, 2009 http://groups.eortc.be/qol/documentation_manuals.
27. Haddy, T. B., Adde, M. A., McCalla, J., Domanski, M. J., Datiles, M. 3rd, Meehan, S. C., et al. (1998). Late effects in long-term survivors of high-grade non-Hodgkin’s lymphomas. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16(6), 2070–2079.
28. Hodgson, D. C. (2008). Hodgkin lymphoma: The follow-up of long-term survivors. Hematology/Oncology Clinics of North America, 22(2), 233–244.
29. Majhail, N. S., Ness, K. K., Burns, L. J., Sun, C. L., Carter, A., Francisco, L., et al. (2007). Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: A report from the bone marrow transplant survivor study. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 13(10), 1153–1159.
30. Oerlemans, S., Mols, F., Nijziel, M. R., Lybeert, M., & van de Poll-Franse, L. V. (2011). The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: A systematic review. Annals of Hematology, 90(9), 993–1004. doi:10.1007/s00277-011-1274-4
31. von der Weid, N. X. (2008). Adult life after surviving lymphoma in childhood. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 16(4), 339–345.
32. van der Poel, M. W., Oerlemans, S., Schouten, H. C., Mols, F., Pruijt, J. F., Maas, H., et al. (2014). Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: A study from the population-based PROFILES registry. Annals of Hematology, 93(5), 811–819. doi:10.1007/s00277-013-1980-1
33. Bachy, E., Houot, R., Morschhauser, F., Sonet, A., Brice, P., Belhadj, K., et al. (2013). Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica, 98(7), 1107–1114. doi:10.3324/haematol.2012.082412
34. Herold, M., Dolken, G., Fiedler, F., Franke, A., Freund, M., Helbig, W., et al. (2003). Randomized phase III study for the treatment of advanced indolent non-Hodgkin’s lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Annals of Hematology, 82(2), 77–79. doi:10.1007/s00277-002-0581-1
35. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., et al. (2005). Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German low-grade Lymphoma study group. Blood, 106(12), 3725–3732. doi:10.1182/blood-2005-01-0016
36. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., et al. (2008). Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(28), 4579–4586. doi:10.1200/JCO.2007.13.5376
37. Oerlemans, S., Issa, D. E., van den Broek, E. C., Nijziel, M. R., Coebergh, J. W., Huijgens, P. C., et al. (2014). Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: Results of the population-based PHAROS-registry. Annals of Hematology, 93(10), 1705–1715. doi:10.1007/s00277-014-2099-8
38. Oerlemans, S., Issa, D. E., van den Broek, E. C., Nijziel, M. R., Coebergh, J. W., Mols, F., et al. (2014). Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: Results of the population-based PHAROS-registry. European Journal of Haematology, 93(3), 229–238. doi:10.1111/ejh.12335
39. Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trneny, M., Bouabdallah, K., et al. (2016). Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial. The Lancet Oncology, 17(8), 1081–1093. doi:10.1016/S1470-2045(16)30097-3
40. Linendoll, N., Saunders, T., Burns, R., Nyce, J. D., Wendell, K. B., Evens, A. M., et al. (2016). Health-related quality of life in Hodgkin lymphoma: A systematic review. Health and Quality of Life Outcomes, 14(1), 114. doi:10.1186/s12955-016-0515-6
41. Jain, N., & O’Brien, S. (2016). Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Reviews, 30(3), 233–244. doi:10.1016/j.blre.2015.12.002
42. Eichhorst, B., Cramer, P., & Hallek, M. (2016). Initial therapy of chronic lymphocytic leukemia. Seminars in Oncology, 43(2), 241–250. doi:10.1053/j.seminoncol.2016.02.005
43. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., et al. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet, 376(9747), 1164–1174. doi:10.1016/S0140-6736(10)61381-5
44. Ghia, P., O’Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., et al. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. Journal of Clinical Oncology. 2014 ASCO Annual Meeting Abstracts, 32(No. 15_suppl), 7099.
45. Wierda, W. G., Chiorazzi, N., Dearden, C., Brown, J. R., Montserrat, E., Shpall, E., et al. (2010). Chronic lymphocytic leukemia: new concepts for future therapy. Clinical Lymphoma Myeloma Leukemia, 10(5), 369–378. doi:10.3816/CLML.2010.n.070
46. Muller, D., Fischer, K., Kaiser, P., Eichhorst, B., Walshe, R., Reiser, M., et al. (2016). Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1130–1139. doi:10.3109/10428194.2015.1070151
47. Groenvold, M., Aaronson, N. K., Darlington, A. S., Fitzsimmons, D., Greimel, E., Holzner, B., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials. Clinical Cancer Research, 22(22), 5617.